Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Exonate

Exonate
2013 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
12 INVESTORS
Description

Developer of small molecule drugs designed to modulate alternative mRNA splicing to address diseases of high unmet medical need. The company's lead program molecules, for wet Age-Related Macular Degeneration (wet AMD), act via a novel mechanism of action to inhibit pathological blood vessel and reduces formation of pathological VEGF (Vascular Endothelial Growth Factor) without inhibiting beneficial, non-pathological VEGF, enabling doctors to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Unit 23, Cambridge Innovation Centre
  • Cambridge Science Park, Milton Road
  • Cambridge CB4 0EY
  • England, United Kingdom

+44 01223 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Exonate’s full profile, request a free trial.

Exonate Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 12-Sep-2018 00.000 Completed Generating Revenue
4. Grant 06-Feb-2017 00.000 00.000 Completed Generating Revenue
3. Early Stage VC 01-Dec-2016 00.00 00.000 00.000 Completed Startup
2. Early Stage VC 05-Oct-2015 $1.21M $1.87M 00.000 Completed Startup
1. Seed Round 01-Mar-2014 $651K $651K 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Exonate Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Ordinary 00,000 00.000000 000 000 00 000 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 7,860 $0.012459 $62.29 $62.29 1x $62.29 14.1%
To view this company’s complete Cap Table, request access »

Exonate Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI 0 0000 000000 0
000000 00000000 Formerly VC-backed Palo Alto, CA 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 00.000 00000000 00.000
000000 00000000000 Venture Capital-Backed Cincinnati, OH 00 00000 000000 - 000 00000
0000000 000000 Venture Capital-Backed Redwood City, CA 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Exonate Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Wellcome Trust Limited Partner 000 0000 000000 0
Martlet Angel Group Minority 000 0000 000000 0
O2h Ventures Venture Capital Minority 000 0000 000000 0
Parkwalk Advisors Venture Capital Minority 000 0000 000000 0
Uniseed Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Exonate Executive Team (5)

Name Title Board
Seat
Contact
Info
Catherine Beech MD Chief Executive Officer & Board Member
David Bates Ph.D Co-Founder, Board Member & Chief Scientific Officer
Christopher O'Connor Financial Controller
Steven Harper Board Member and Medical Director
Lucy Donaldson Ph.D Founding Scientist

Exonate Board Members (7)

Name Representing Role Since Contact
Info
Andrew Naylor Ph.D Self Board Member 000 0000
Catherine Beech MD Exonate Chief Executive Officer & Board Member 000 0000
Christopher Torrance Ph.D Self Board Member 000 0000
David Bates Ph.D Exonate Co-Founder, Board Member & Chief Scientific Officer 000 0000
John Kurek Ph.D Uniseed Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »